(Q30413920)

22 August 2017

Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups (English)

1 reference

22 August 2017

phase III clinical trial

0 references

Daniel J Sargent

8

0 references

Craig Slingluff

12

object named as

Craig L Slingluff

1 reference

22 August 2017

11

Benjamin Djulbegovic

1 reference

22 August 2017

Anneke T Schroen

1

1 reference

22 August 2017

Gina R Petroni

2

1 reference

22 August 2017

Hongkun Wang

3

1 reference

22 August 2017

Monika J Thielen

4

1 reference

22 August 2017

Robert Gray

5

1 reference

22 August 2017

Jacqueline Benedetti

6

1 reference

22 August 2017

Xiaofei F Wang

7

1 reference

22 August 2017

Donald L Wickerham

9

1 reference

22 August 2017

Walter Cronin

10

1 reference

22 August 2017

language of work or name

English

0 references

publication date

5 October 2011

1 reference

22 August 2017

Clinical Cancer Research

1 reference

22 August 2017

18

1 reference

22 August 2017

1

1 reference

22 August 2017

256-262

1 reference

Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Steps and time to process clinical trials at the Cancer Therapy Evaluation Program

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Time to publication for results of clinical trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Trends in UK cancer trials: results from the UK Coordinating Committee for Cancer Research National Register of Cancer Trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Factors that limit the quality, number and progress of randomised controlled trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Applying results of randomised trials to clinical practice: impact of losses before randomisation.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3977198

Planning patient recruitment: fantasy and reality

20 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21976533

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21976533

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-11-1633

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

21976533

1 reference